藥物設計 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "藥物設計" in Chinese language version.
refsWebsite
Global rank
Chinese rank
11th place
332nd place
6th place
4th place
1st place
1st place
9,524th place
325th place
18th place
57th place
archive.org (Global: 6th place; Chinese: 4th place)
- Wu-Pong S, Rojanasakul Y. Biopharmaceutical drug design and development 2nd. Totowa, NJ Humana Press: Humana Press. 2008. ISBN 978-1-59745-532-9.
- Lewis RA. Chapter 4: The Development of Molecular Modelling Programs: The Use and Limitations of Physical Models. RSC Drug Discovery. Royal Society of Chemistry. 2011: 88–107. ISBN 978-1849731669. doi:10.1039/9781849733410-00088.
- Guner OF. Pharmacophore Perception, Development, and use in Drug Design. La Jolla, Calif: International University Line. 2000. ISBN 978-0-9636817-6-8.
- Leach AR, Harren J. Structure-based Drug Discovery. Berlin: Springer. 2007. ISBN 978-1-4020-4406-9.
- Warren GL, Warren SD. Chapter 16: Scoring Drug-Receptor Interactions. RSC Drug Discovery. Royal Society of Chemistry. 2011: 440–457. ISBN 978-1849731669. doi:10.1039/9781849733410-00440.
- Gramatica P. Chapter 17: Modeling Chemicals in the Environment. RSC Drug Discovery. Royal Society of Chemistry. 2011: 466. ISBN 978-1849731669. doi:10.1039/9781849733410-00458.
bio.org (Global: low place; Chinese: low place)
- New Clinical Development Success Rates 2011-2020 Report. BIO, Informa Pharma Intelligence, and QLS Advisors. Feb 2021 [2023-06-20]. （原始内容存档于2023-02-08）.
doi.org (Global: 2nd place; Chinese: 23rd place)
- Shirai H, Prades C, Vita R, Marcatili P, Popovic B, Xu J, Overington JP, Hirayama K, Soga S, Tsunoyama K, Clark D, Lefranc MP, Ikeda K. Antibody informatics for drug discovery. Biochimica et Biophysica Acta. Nov 2014, 1844 (11): 2002–2015. PMID 25110827. doi:10.1016/j.bbapap.2014.07.006.
- Tollenaere JP. The role of structure-based ligand design and molecular modelling in drug discovery. Pharmacy World & Science. Apr 1996, 18 (2): 56–62. PMID 8739258. S2CID 21550508. doi:10.1007/BF00579706.
- Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery. 2015, 14 (7): 475–86. PMID 26091267. S2CID 25292436. doi:10.1038/nrd4609.
- Yu H, Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discovery Today. Sep 2003, 8 (18): 852–61. PMID 12963322. doi:10.1016/S1359-6446(03)02828-9.
- Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Current Opinion in Chemical Biology. Dec 2009, 13 (5–6): 549–55. PMC 2787993
. PMID 19740696. doi:10.1016/j.cbpa.2009.08.003. - Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Reviews. Drug Discovery. Oct 2006, 5 (10): 821–34. PMID 17016423. S2CID 8872470. doi:10.1038/nrd2132.
- Anderson AC. The process of structure-based drug design. Chemistry & Biology. Sep 2003, 10 (9): 787–97. PMID 14522049. doi:10.1016/j.chembiol.2003.09.002 .
- Recanatini M, Bottegoni G, Cavalli A. In silico antitarget screening. Drug Discovery Today: Technologies. Dec 2004, 1 (3): 209–15. PMID 24981487. doi:10.1016/j.ddtec.2004.10.004.
- Scomparin A, Polyak D, Krivitsky A, Satchi-Fainaro R. Achieving successful delivery of oligonucleotides - From physico-chemical characterization to in vivo evaluation. Biotechnology Advances. Apr 2015, 33 (6): 1294–309. PMID 25916823. doi:10.1016/j.biotechadv.2015.04.008.
- Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Current Pharmaceutical Design. Dec 2013, 19 (12): 2326–33. PMID 23082974. doi:10.2174/1381612811319120019.
- Rishton GM. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today. Jan 2003, 8 (2): 86–96. PMID 12565011. doi:10.1016/s1359644602025722.
- Ethiraj SK, Levinthal D. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly (Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University). Sep 2004, 49 (3): 404–437 [2023-05-04]. JSTOR 4131441. S2CID 142910916. SSRN 604123 . doi:10.2307/4131441. （原始内容存档于2022-05-26）.
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. January 2015, 20 (1): 122–128. PMID 25450771. doi:10.1016/j.drudis.2014.10.003 .Fosgerau K, Hoffmann T (January 2015). "Peptide therapeutics: current status and future directions". Drug Discovery Today. 20 (1): 122–128. doi:10.1016/j.drudis.2014.10.003. PMID 25450771 （页面存档备份，存于互联网档案馆）.
- Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S. Protein-peptide docking: opportunities and challenges. Drug Discovery Today. August 2018, 23 (8): 1530–1537. PMID 29733895. doi:10.1016/j.drudis.2018.05.006 .Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S (August 2018). "Protein-peptide docking: opportunities and challenges". Drug Discovery Today. 23 (8): 1530–1537. doi:10.1016/j.drudis.2018.05.006. PMID 29733895 （页面存档备份，存于互联网档案馆）.
- Lewis RA. Chapter 4: The Development of Molecular Modelling Programs: The Use and Limitations of Physical Models. RSC Drug Discovery. Royal Society of Chemistry. 2011: 88–107. ISBN 978-1849731669. doi:10.1039/9781849733410-00088.
- de Azevedo WF, Dias R. Computational methods for calculation of ligand-binding affinity. Current Drug Targets. Dec 2008, 9 (12): 1031–9. PMID 19128212. doi:10.2174/138945008786949405.
- Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorganic & Medicinal Chemistry Letters. Dec 2003, 13 (24): 4355–9. PMID 14643325. doi:10.1016/j.bmcl.2003.09.028.
- Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. Journal of Medicinal Chemistry. Jun 2006, 49 (11): 3116–35. PMID 16722631. doi:10.1021/jm0508641.
- Liang S, Meroueh SO, Wang G, Qiu C, Zhou Y. Consensus scoring for enriching near-native structures from protein-protein docking decoys. Proteins. May 2009, 75 (2): 397–403. PMC 2656599 . PMID 18831053. doi:10.1002/prot.22252.
- Oda A, Tsuchida K, Takakura T, Yamaotsu N, Hirono S. Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes. Journal of Chemical Information and Modeling. 2006, 46 (1): 380–91. PMID 16426072. doi:10.1021/ci050283k.
- Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. Journal of Medicinal Chemistry. Jan 2004, 47 (2): 337–44. PMID 14711306. doi:10.1021/jm030331x.
- Amari S, Aizawa M, Zhang J, Fukuzawa K, Mochizuki Y, Iwasawa Y, Nakata K, Chuman H, Nakano T. VISCANA: visualized cluster analysis of protein-ligand interaction based on the ab initio fragment molecular orbital method for virtual ligand screening. Journal of Chemical Information and Modeling. 2006, 46 (1): 221–30. PMID 16426058. doi:10.1021/ci050262q.
- Klebe G. Recent developments in structure-based drug design. Journal of Molecular Medicine. 2000, 78 (5): 269–81. PMID 10954199. S2CID 21314020. doi:10.1007/s001090000084.
- Wang R, Gao Y, Lai L. LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design. Journal of Molecular Modeling. 2000, 6 (7–8): 498–516. S2CID 59482623. doi:10.1007/s0089400060498.
- Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nature Reviews. Drug Discovery. Aug 2005, 4 (8): 649–63. PMID 16056391. S2CID 2549851. doi:10.1038/nrd1799.
- Jorgensen WL. The many roles of computation in drug discovery. Science. Mar 2004, 303 (5665): 1813–8. Bibcode:2004Sci...303.1813J. PMID 15031495. S2CID 1307935. doi:10.1126/science.1096361.
- Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Current Pharmaceutical Design. Dec 2013, 19 (12): 2326–33. PMID 23082974. doi:10.2174/1381612811319120019.Yuan Y, Pei J, Lai L (Dec 2013). "Binding site detection and druggability prediction of protein targets for structure-based drug design". Current Pharmaceutical Design. 19 (12): 2326–33. doi:10.2174/1381612811319120019. PMID 23082974 （页面存档备份，存于互联网档案馆）.
- Leis S, Schneider S, Zacharias M. In silico prediction of binding sites on proteins. Current Medicinal Chemistry. 2010, 17 (15): 1550–62. PMID 20166931. doi:10.2174/092986710790979944.
- Warren GL, Warren SD. Chapter 16: Scoring Drug-Receptor Interactions. RSC Drug Discovery. Royal Society of Chemistry. 2011: 440–457. ISBN 978-1849731669. doi:10.1039/9781849733410-00440.
- Böhm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. Journal of Computer-Aided Molecular Design. Jun 1994, 8 (3): 243–56. Bibcode:1994JCAMD...8..243B. PMID 7964925. S2CID 2491616. doi:10.1007/BF00126743.
- Liu J, Wang R. Classification of Current Scoring Functions. Journal of Chemical Information and Modeling. 23 March 2015, 55 (3): 475–482. PMID 25647463. doi:10.1021/ci500731a.
- Ajay, Murcko MA. Computational methods to predict binding free energy in ligand-receptor complexes. J. Med. Chem. 1995, 38 (26): 4953–67. PMID 8544170. doi:10.1021/jm00026a001.
- Gramatica P. Chapter 17: Modeling Chemicals in the Environment. RSC Drug Discovery. Royal Society of Chemistry. 2011: 466. ISBN 978-1849731669. doi:10.1039/9781849733410-00458.
- Greer J, Erickson JW, Baldwin JJ, Varney MD. Application of the three-dimensional structures of protein target molecules in structure-based drug design. Journal of Medicinal Chemistry. Apr 1994, 37 (8): 1035–54. PMID 8164249. doi:10.1021/jm00034a001.
- Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug Discovery. Jul 2002, 1 (7): 493–502. PMID 12120256. S2CID 2728341. doi:10.1038/nrd839.
- Klein DF. The loss of serendipity in psychopharmacology. JAMA. Mar 2008, 299 (9): 1063–5. PMID 18319418. doi:10.1001/jama.299.9.1063.
harvard.edu (Global: 18th place; Chinese: 57th place)
ui.adsabs.harvard.edu
- Jorgensen WL. The many roles of computation in drug discovery. Science. Mar 2004, 303 (5665): 1813–8. Bibcode:2004Sci...303.1813J. PMID 15031495. S2CID 1307935. doi:10.1126/science.1096361.
- Böhm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. Journal of Computer-Aided Molecular Design. Jun 1994, 8 (3): 243–56. Bibcode:1994JCAMD...8..243B. PMID 7964925. S2CID 2491616. doi:10.1007/BF00126743.
jstor.org (Global: 26th place; Chinese: 113th place)
- Ethiraj SK, Levinthal D. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly (Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University). Sep 2004, 49 (3): 404–437 [2023-05-04]. JSTOR 4131441. S2CID 142910916. SSRN 604123 . doi:10.2307/4131441. （原始内容存档于2022-05-26）.
nih.gov (Global: 4th place; Chinese: 5th place)
ncbi.nlm.nih.gov
- Shirai H, Prades C, Vita R, Marcatili P, Popovic B, Xu J, Overington JP, Hirayama K, Soga S, Tsunoyama K, Clark D, Lefranc MP, Ikeda K. Antibody informatics for drug discovery. Biochimica et Biophysica Acta. Nov 2014, 1844 (11): 2002–2015. PMID 25110827. doi:10.1016/j.bbapap.2014.07.006.
- Tollenaere JP. The role of structure-based ligand design and molecular modelling in drug discovery. Pharmacy World & Science. Apr 1996, 18 (2): 56–62. PMID 8739258. S2CID 21550508. doi:10.1007/BF00579706.
- Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery. 2015, 14 (7): 475–86. PMID 26091267. S2CID 25292436. doi:10.1038/nrd4609.
- Yu H, Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discovery Today. Sep 2003, 8 (18): 852–61. PMID 12963322. doi:10.1016/S1359-6446(03)02828-9.
- Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Current Opinion in Chemical Biology. Dec 2009, 13 (5–6): 549–55. PMC 2787993 . PMID 19740696. doi:10.1016/j.cbpa.2009.08.003.
- Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Reviews. Drug Discovery. Oct 2006, 5 (10): 821–34. PMID 17016423. S2CID 8872470. doi:10.1038/nrd2132.
- Anderson AC. The process of structure-based drug design. Chemistry & Biology. Sep 2003, 10 (9): 787–97. PMID 14522049. doi:10.1016/j.chembiol.2003.09.002 .
- Recanatini M, Bottegoni G, Cavalli A. In silico antitarget screening. Drug Discovery Today: Technologies. Dec 2004, 1 (3): 209–15. PMID 24981487. doi:10.1016/j.ddtec.2004.10.004.
- Scomparin A, Polyak D, Krivitsky A, Satchi-Fainaro R. Achieving successful delivery of oligonucleotides - From physico-chemical characterization to in vivo evaluation. Biotechnology Advances. Apr 2015, 33 (6): 1294–309. PMID 25916823. doi:10.1016/j.biotechadv.2015.04.008.
- Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Current Pharmaceutical Design. Dec 2013, 19 (12): 2326–33. PMID 23082974. doi:10.2174/1381612811319120019.
- Rishton GM. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today. Jan 2003, 8 (2): 86–96. PMID 12565011. doi:10.1016/s1359644602025722.
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. January 2015, 20 (1): 122–128. PMID 25450771. doi:10.1016/j.drudis.2014.10.003 .Fosgerau K, Hoffmann T (January 2015). "Peptide therapeutics: current status and future directions". Drug Discovery Today. 20 (1): 122–128. doi:10.1016/j.drudis.2014.10.003. PMID 25450771 （页面存档备份，存于互联网档案馆）.
- Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S. Protein-peptide docking: opportunities and challenges. Drug Discovery Today. August 2018, 23 (8): 1530–1537. PMID 29733895. doi:10.1016/j.drudis.2018.05.006 .Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S (August 2018). "Protein-peptide docking: opportunities and challenges". Drug Discovery Today. 23 (8): 1530–1537. doi:10.1016/j.drudis.2018.05.006. PMID 29733895 （页面存档备份，存于互联网档案馆）.
- Rajamani R, Good AC. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development. Current Opinion in Drug Discovery & Development. May 2007, 10 (3): 308–15. PMID 17554857.
- de Azevedo WF, Dias R. Computational methods for calculation of ligand-binding affinity. Current Drug Targets. Dec 2008, 9 (12): 1031–9. PMID 19128212. doi:10.2174/138945008786949405.
- Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorganic & Medicinal Chemistry Letters. Dec 2003, 13 (24): 4355–9. PMID 14643325. doi:10.1016/j.bmcl.2003.09.028.
- Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. Journal of Medicinal Chemistry. Jun 2006, 49 (11): 3116–35. PMID 16722631. doi:10.1021/jm0508641.
- Liang S, Meroueh SO, Wang G, Qiu C, Zhou Y. Consensus scoring for enriching near-native structures from protein-protein docking decoys. Proteins. May 2009, 75 (2): 397–403. PMC 2656599 . PMID 18831053. doi:10.1002/prot.22252.
- Oda A, Tsuchida K, Takakura T, Yamaotsu N, Hirono S. Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes. Journal of Chemical Information and Modeling. 2006, 46 (1): 380–91. PMID 16426072. doi:10.1021/ci050283k.
- Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. Journal of Medicinal Chemistry. Jan 2004, 47 (2): 337–44. PMID 14711306. doi:10.1021/jm030331x.
- Amari S, Aizawa M, Zhang J, Fukuzawa K, Mochizuki Y, Iwasawa Y, Nakata K, Chuman H, Nakano T. VISCANA: visualized cluster analysis of protein-ligand interaction based on the ab initio fragment molecular orbital method for virtual ligand screening. Journal of Chemical Information and Modeling. 2006, 46 (1): 221–30. PMID 16426058. doi:10.1021/ci050262q.
- Mauser H, Guba W. Recent developments in de novo design and scaffold hopping. Current Opinion in Drug Discovery & Development. May 2008, 11 (3): 365–74. PMID 18428090.
- Klebe G. Recent developments in structure-based drug design. Journal of Molecular Medicine. 2000, 78 (5): 269–81. PMID 10954199. S2CID 21314020. doi:10.1007/s001090000084.
- Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nature Reviews. Drug Discovery. Aug 2005, 4 (8): 649–63. PMID 16056391. S2CID 2549851. doi:10.1038/nrd1799.
- Jorgensen WL. The many roles of computation in drug discovery. Science. Mar 2004, 303 (5665): 1813–8. Bibcode:2004Sci...303.1813J. PMID 15031495. S2CID 1307935. doi:10.1126/science.1096361.
- Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Current Pharmaceutical Design. Dec 2013, 19 (12): 2326–33. PMID 23082974. doi:10.2174/1381612811319120019.Yuan Y, Pei J, Lai L (Dec 2013). "Binding site detection and druggability prediction of protein targets for structure-based drug design". Current Pharmaceutical Design. 19 (12): 2326–33. doi:10.2174/1381612811319120019. PMID 23082974 （页面存档备份，存于互联网档案馆）.
- Leis S, Schneider S, Zacharias M. In silico prediction of binding sites on proteins. Current Medicinal Chemistry. 2010, 17 (15): 1550–62. PMID 20166931. doi:10.2174/092986710790979944.
- Böhm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. Journal of Computer-Aided Molecular Design. Jun 1994, 8 (3): 243–56. Bibcode:1994JCAMD...8..243B. PMID 7964925. S2CID 2491616. doi:10.1007/BF00126743.
- Liu J, Wang R. Classification of Current Scoring Functions. Journal of Chemical Information and Modeling. 23 March 2015, 55 (3): 475–482. PMID 25647463. doi:10.1021/ci500731a.
- Ajay, Murcko MA. Computational methods to predict binding free energy in ligand-receptor complexes. J. Med. Chem. 1995, 38 (26): 4953–67. PMID 8544170. doi:10.1021/jm00026a001.
- Greer J, Erickson JW, Baldwin JJ, Varney MD. Application of the three-dimensional structures of protein target molecules in structure-based drug design. Journal of Medicinal Chemistry. Apr 1994, 37 (8): 1035–54. PMID 8164249. doi:10.1021/jm00034a001.
- Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug Discovery. Jul 2002, 1 (7): 493–502. PMID 12120256. S2CID 2728341. doi:10.1038/nrd839.
- Klein DF. The loss of serendipity in psychopharmacology. JAMA. Mar 2008, 299 (9): 1063–5. PMID 18319418. doi:10.1001/jama.299.9.1063.
pubmed.ncbi.nlm.nih.gov
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. January 2015, 20 (1): 122–128. PMID 25450771. doi:10.1016/j.drudis.2014.10.003 .Fosgerau K, Hoffmann T (January 2015). "Peptide therapeutics: current status and future directions". Drug Discovery Today. 20 (1): 122–128. doi:10.1016/j.drudis.2014.10.003. PMID 25450771 （页面存档备份，存于互联网档案馆）.
- Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S. Protein-peptide docking: opportunities and challenges. Drug Discovery Today. August 2018, 23 (8): 1530–1537. PMID 29733895. doi:10.1016/j.drudis.2018.05.006 .Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S (August 2018). "Protein-peptide docking: opportunities and challenges". Drug Discovery Today. 23 (8): 1530–1537. doi:10.1016/j.drudis.2018.05.006. PMID 29733895 （页面存档备份，存于互联网档案馆）.
- Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Current Pharmaceutical Design. Dec 2013, 19 (12): 2326–33. PMID 23082974. doi:10.2174/1381612811319120019.Yuan Y, Pei J, Lai L (Dec 2013). "Binding site detection and druggability prediction of protein targets for structure-based drug design". Current Pharmaceutical Design. 19 (12): 2326–33. doi:10.2174/1381612811319120019. PMID 23082974 （页面存档备份，存于互联网档案馆）.
semanticscholar.org (Global: 11th place; Chinese: 332nd place)
api.semanticscholar.org
- Tollenaere JP. The role of structure-based ligand design and molecular modelling in drug discovery. Pharmacy World & Science. Apr 1996, 18 (2): 56–62. PMID 8739258. S2CID 21550508. doi:10.1007/BF00579706.
- Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery. 2015, 14 (7): 475–86. PMID 26091267. S2CID 25292436. doi:10.1038/nrd4609.
- Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Reviews. Drug Discovery. Oct 2006, 5 (10): 821–34. PMID 17016423. S2CID 8872470. doi:10.1038/nrd2132.
- Ethiraj SK, Levinthal D. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly (Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University). Sep 2004, 49 (3): 404–437 [2023-05-04]. JSTOR 4131441. S2CID 142910916. SSRN 604123 . doi:10.2307/4131441. （原始内容存档于2022-05-26）.
- Klebe G. Recent developments in structure-based drug design. Journal of Molecular Medicine. 2000, 78 (5): 269–81. PMID 10954199. S2CID 21314020. doi:10.1007/s001090000084.
- Wang R, Gao Y, Lai L. LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design. Journal of Molecular Modeling. 2000, 6 (7–8): 498–516. S2CID 59482623. doi:10.1007/s0089400060498.
- Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nature Reviews. Drug Discovery. Aug 2005, 4 (8): 649–63. PMID 16056391. S2CID 2549851. doi:10.1038/nrd1799.
- Jorgensen WL. The many roles of computation in drug discovery. Science. Mar 2004, 303 (5665): 1813–8. Bibcode:2004Sci...303.1813J. PMID 15031495. S2CID 1307935. doi:10.1126/science.1096361.
- Böhm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. Journal of Computer-Aided Molecular Design. Jun 1994, 8 (3): 243–56. Bibcode:1994JCAMD...8..243B. PMID 7964925. S2CID 2491616. doi:10.1007/BF00126743.
- Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug Discovery. Jul 2002, 1 (7): 493–502. PMID 12120256. S2CID 2728341. doi:10.1038/nrd839.
ssrn.com (Global: 703rd place; Chinese: 1,016th place)
- Ethiraj SK, Levinthal D. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly (Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University). Sep 2004, 49 (3): 404–437 [2023-05-04]. JSTOR 4131441. S2CID 142910916. SSRN 604123 . doi:10.2307/4131441. （原始内容存档于2022-05-26）.
termonline.cn (Global: 9,524th place; Chinese: 325th place)
- 理性药物设计. 术语在线. 全国科学技术名词审定委员会. （简体中文）
- 合理药物设计. 术语在线. 全国科学技术名词审定委员会. （简体中文）
upenn.edu (Global: 702nd place; Chinese: 1,153rd place)
repository.upenn.edu
- Ethiraj SK, Levinthal D. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly (Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University). Sep 2004, 49 (3): 404–437 [2023-05-04]. JSTOR 4131441. S2CID 142910916. SSRN 604123 . doi:10.2307/4131441. （原始内容存档于2022-05-26）.
web.archive.org (Global: 1st place; Chinese: 1st place)
- New Clinical Development Success Rates 2011-2020 Report. BIO, Informa Pharma Intelligence, and QLS Advisors. Feb 2021 [2023-06-20]. （原始内容存档于2023-02-08）.
- Ethiraj SK, Levinthal D. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly (Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University). Sep 2004, 49 (3): 404–437 [2023-05-04]. JSTOR 4131441. S2CID 142910916. SSRN 604123 . doi:10.2307/4131441. （原始内容存档于2022-05-26）.
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. January 2015, 20 (1): 122–128. PMID 25450771. doi:10.1016/j.drudis.2014.10.003 .Fosgerau K, Hoffmann T (January 2015). "Peptide therapeutics: current status and future directions". Drug Discovery Today. 20 (1): 122–128. doi:10.1016/j.drudis.2014.10.003. PMID 25450771 （页面存档备份，存于互联网档案馆）.
- Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S. Protein-peptide docking: opportunities and challenges. Drug Discovery Today. August 2018, 23 (8): 1530–1537. PMID 29733895. doi:10.1016/j.drudis.2018.05.006 .Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S (August 2018). "Protein-peptide docking: opportunities and challenges". Drug Discovery Today. 23 (8): 1530–1537. doi:10.1016/j.drudis.2018.05.006. PMID 29733895 （页面存档备份，存于互联网档案馆）.
- Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Current Pharmaceutical Design. Dec 2013, 19 (12): 2326–33. PMID 23082974. doi:10.2174/1381612811319120019.Yuan Y, Pei J, Lai L (Dec 2013). "Binding site detection and druggability prediction of protein targets for structure-based drug design". Current Pharmaceutical Design. 19 (12): 2326–33. doi:10.2174/1381612811319120019. PMID 23082974 （页面存档备份，存于互联网档案馆）.